CD38 and Miyoshi myopathy: Incorporation of a targeting moiety to LNPs can significantly enhance the efficiency and specificity of the delivery to hard‐to‐transfect cells, such as lymphocytes.[8] We chose to target CD38, a glycoprotein which is overly expressed upon MM cells and many other B‐cell lymphoma cells such as mantle cell lymphoma.[21, 22] CD38 was also shown to be clinically relevant for MM with Daratumumab, the first monoclonal antibody approved for treatment of MM.[23]